SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

AZTR

Azitra, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed4d 8h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Watch for topline data from ATR-04 Cohort 1 and initial ATR-COSF cosmetic study results, both expected by year-end 2026. Positive data could trigger the additional $5.25M-$10.5M investment from institutional investors, extending the cash runway.

DirectionNeutral
Confidencemedium
Horizonweeks

Drugs in focus

AZTR drug pipeline →

ATR-04

◆ Mixed Named in this press release
Impact
Phase
Phase 1/2
Time to market
Unknown — at least 3-5 years if Phase 1/2 data is positive, followed by Phase 3 trials and FDA review. The Fast Track designation could accelerate the timeline.
Next catalyst
None dated

What to watchWatch for ATR-04 Phase 1/2 first-cohort topline data expected Q4 2026, positive safety/efficacy signals could drive a sharp rally given the tiny market cap, but the ~6-month cash runway means a dilutive financing is likely before year-end regardless of results. The stock is a high-risk binary play on a single early-stage asset.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$0.6084
T+0 close · Nov 12, 2026 · via day close
Latest settled
+3.06%
T+1 · $0.6270
Vs SPY
+4.97%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $0.6084entry
  2. T+1 · yesterday +3.06%α +4.97% · $0.6270
  3. T+2 · todayOpen
  4. T+5 · in 3d Pending
  5. T+20 · in 27d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Azitra reported a Q3 2026 net loss of $3.0M ($0.29 per share), wider than the $2.8M loss a year ago, with cash of $3.8M. The key catalysts are upcoming topline data from the ATR-04 Phase 1/2 trial (Cohort 1) and initial results from the ATR-COSF first-in-human cosmetic study, both expected by year-end 2026. The company also noted that institutional investors may invest an additional $5.25M to $10.5M after the ATR-COSF results are announced.

Key Financial Metrics

EPS
−$0.29
est −$0.25 · -16.0%
Rating
miss

Key Facts

  • Net loss of $3.0M for Q3 2026, compared to $2.8M in Q3 2025
  • Cash and cash equivalents of $3.8M as of September 30, 2026
  • ATR-04 Phase 1/2 trial completed Cohort 1; safety committee recommended proceeding to Cohort 2
  • Topline data from ATR-04 Cohort 1 expected in Q4 2026
  • First-in-human cosmetic study of ATR-COSF planned with initial results expected by year-end 2026
  • Institutional investors may invest an additional $5.25M to $10.5M after ATR-COSF results are announced

Financial Impact

Net loss increased $0.2M year-over-year; cash burn rate suggests runway of approximately 3-4 quarters at current spending levels

net losscash and cash equivalents

Risk Factors

  • Cash and cash equivalents of $3.8M may not be sufficient to fund operations beyond mid-2027 without additional financing
  • Clinical-stage company with no approved products or revenue; results from ex vivo studies may not translate to human trials
  • Potential dilution from exercise of financial instruments issued in the March 2026 private placement

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302938286

Track record

16 reports on AZTR

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.73% at T+60 after the May 21, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13D Neutral 5/10 Entry $0.5805 Now $0.6090 +4.91% settles Feb 16
  2. Nov 12, 20264d ago Press Release Neutral 4/10 Viewing Entry $0.6084 Now $0.6090 +0.10% settles Feb 11
  3. Nov 12, 20264d ago 8-K Neutral 4/10 No price data
  4. Nov 12, 20265d ago SC 13G/A Neutral 2/10 Entry $0.6685 Now $0.6090 −8.90% settles Feb 10
  5. Nov 10, 20267d ago 8-K Neutral 3/10 Entry $0.6000 Now $0.6090 +1.50% settles Feb 8
  6. Nov 10, 20267d ago Press Release Neutral 3/10 Entry $0.6000 Now $0.6090 +1.50% settles Feb 8
  7. Oct 29, 202619d ago 8-K Neutral 3/10 Entry $0.7571 Now $0.6090 −19.56% settles Jan 27
  8. Oct 26, 202622d ago 8-K Neutral 4/10 Entry $1.53 Now $0.6090 −60.20% settles Jan 22
  9. Oct 22, 202626d ago 8-K Neutral 3/10 Entry $0.0715 Now $0.6090 +751.75% settles Jan 21
  10. Oct 1, 20266w ago 8-K Neutral 4/10 Entry $0.1285 Now $0.6090 +373.93% settles Dec 28
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (17h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026